跳至主要内容
临床试验/NCT00625365
NCT00625365已完成4 期

CARES (Contrast EchocArdiography REgistry for Safety Surveillance): A Prospective, Phase IV, Open-Label, Nonrandomized, Multicenter, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice

Lantheus Medical Imaging16 个研究点 分布在 1 个国家目标入组 1,060 人开始时间: 2008年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
1,060
试验地点
16
主要终点
The Number and Percentage of Patients With Death or Life Threatening Cardiopulmonary Events Occurring Following Definity Administration

研究概览

简要总结

The purpose of this registry study is to gather safety information on the current clinical use of and the safety of DEFINITY®

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

DEFINITY® (Perflutren Lipid Microsphere)

Other

Patients who had undergone unenhanced echocardiography yielding suboptimal images and who were determined by the Principal Investigator to require DEFINITY-enhanced echocardiography

干预措施: DEFINITY® (Drug)

结局指标

主要结局

The Number and Percentage of Patients With Death or Life Threatening Cardiopulmonary Events Occurring Following Definity Administration

时间窗: during or within 30 minutes of administration

次要结局

  • Serious Adverse Events(Through 24 hours)
  • Adverse Events(Through 24 hours)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验

A Prospective, Phase IV, Surveillance Registry Study... | 临床试验